Bristol Myers Squibb has received US FDA approval for Sotyktu (deucravacitinib) for the treatment of adult patients with active psoriatic arthritis (PsA).[1][2][6] It is the first selective oral TYK2 inhibitor approved for this indication.[1][2][5] The approval follows positive results from the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 studies that tested Sotykta at a dose of 6 mg once daily.[1][2][4] In both studies, patients treated with Sotykta achieved a significant improvement in disease activity versus placebo, as measured by the primary endpoint of ACR20 (at least 20% improvement in symptoms) at 16 weeks.[1][2][4][5] A key secondary endpoint was Minimal Disease Activity (MDA) response.[1][2] The POETYK PsA-1 study included 670 biologic-naïve patients and the POETYK PsA-2 study included 730 patients, including those after TNF blockers.[4] Sotyktu was originally approved in 2022 for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.[1][7]